FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

View source ↗

Summary

FDA grants accelerated approval for Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for treatment-resistant advanced m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tudriqev (vusolimogene oderparepvec-wtpg)

Snippet

The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.